<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30509771</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1474-5488</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>20</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Lancet. Oncology</Title>
          <ISOAbbreviation>Lancet Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.</ArticleTitle>
        <Pagination>
          <StartPage>88</StartPage>
          <EndPage>99</EndPage>
          <MedlinePgn>88-99</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/S1470-2045(18)30621-1</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1470-2045(18)30621-1</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">The optimal duration of extended therapy with aromatase inhibitors in patients with postmenopausal breast cancer is unknown. In the NSABP B-42 study, we aimed to determine whether extended letrozole treatment improves disease-free survival after 5 years of aromatase inhibitor-based therapy in women with postmenopausal breast cancer.</AbstractText>
          <AbstractText Label="METHODS">This randomised, double-blind, placebo-controlled, phase 3 trial was done in 158 centres in the USA, Canada, and Ireland. Postmenopausal women with stage I-IIIA hormone receptor-positive breast cancer, who were disease-free after about 5 years of treatment with an aromatase inhibitor or tamoxifen followed by an aromatase inhibitor, were randomly assigned (1:1) to receive 5 years of letrozole (2·5 mg orally per day) or placebo. Randomisation was stratified by pathological node status, previous tamoxifen use, and lowest bone mineral density T score in the lumbosacral spine, total hip, or femoral neck. The primary endpoint was disease-free survival, defined as time from randomisation to breast cancer recurrence, second primary malignancy, or death, and was analysed by intention to treat. To adjust for previous interim analyses, the two-sided statistical significance level for disease-free survival was set at 0·0418. This study is registered with ClinicalTrials.gov, number NCT00382070, is active, and is no longer enrolling patients.</AbstractText>
          <AbstractText Label="FINDINGS">Between Sept 28, 2006, and Jan 6, 2010, 3966 patients were randomly assigned to receive letrozole (n=1983) or placebo (n=1983). Follow-up information was available for 3903 patients for the analyses of disease-free survival. Median follow-up was 6·9 years (IQR 6·1-7·5). Letrozole treatment did not significantly improve disease-free survival (339 disease-free survival events were reported in the placebo group and 292 disease-free survival events were reported in the letrozole group; hazard ratio 0·85, 95% CI 0·73-0·999; p=0·048). 7-year disease-free survival estimate was 81·3% (95% CI 79·3-83·1) in the placebo group and 84·7% (82·9-86·4) in the letrozole group. The most common grade 3 adverse events were arthralgia (47 [2%] of 1933 patients in the placebo group vs 50 [3%] of 1941 patients in the letrozole group) and back pain (44 [2%] vs 38 [2%]). The most common grade 4 adverse event in the placebo group was thromboembolic event (eight [&lt;1%]) and the most common grade 4 adverse events in the letrozole group were urinary tract infection, hypokalaemia, and left ventricular systolic dysfunction (four [&lt;1%] each).</AbstractText>
          <AbstractText Label="INTERPRETATION">After 5 years of aromatase inhibitor-based therapy, 5 years of letrozole therapy did not significantly prolong disease-free survival compared with placebo. Careful assessment of potential risks and benefits is required before recommending extended letrozole therapy to patients with early-stage breast cancer.</AbstractText>
          <AbstractText Label="FUNDING">National Cancer Institute, Korea Health Technology R&amp;D Project, Novartis.</AbstractText>
          <CopyrightInformation>Copyright © 2019 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mamounas</LastName>
            <ForeName>Eleftherios P</ForeName>
            <Initials>EP</Initials>
            <AffiliationInfo>
              <Affiliation>NRG Oncology/NSABP, Pittsburgh, PA, USA; UF Health Cancer Center at Orlando Health, Orlando, FL, USA. Electronic address: terry.mamounas@orlandohealth.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bandos</LastName>
            <ForeName>Hanna</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>NRG Oncology/NSABP, Pittsburgh, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lembersky</LastName>
            <ForeName>Barry C</ForeName>
            <Initials>BC</Initials>
            <AffiliationInfo>
              <Affiliation>NRG Oncology/NSABP, Pittsburgh, PA, USA; The University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jeong</LastName>
            <ForeName>Jong-Hyeon</ForeName>
            <Initials>JH</Initials>
            <AffiliationInfo>
              <Affiliation>NRG Oncology/NSABP, Pittsburgh, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Geyer</LastName>
            <ForeName>Charles E</ForeName>
            <Initials>CE</Initials>
            <Suffix>Jr</Suffix>
            <AffiliationInfo>
              <Affiliation>NRG Oncology/NSABP, Pittsburgh, PA, USA; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rastogi</LastName>
            <ForeName>Priya</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>NRG Oncology/NSABP, Pittsburgh, PA, USA; The University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fehrenbacher</LastName>
            <ForeName>Louis</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>NRG Oncology/NSABP, Pittsburgh, PA, USA; Kaiser Permanente Oncology Clinical Trials Northern California, Vallejo, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Graham</LastName>
            <ForeName>Mark L</ForeName>
            <Initials>ML</Initials>
            <AffiliationInfo>
              <Affiliation>NRG Oncology/NSABP, Pittsburgh, PA, USA; Southeast Cancer Control Consortium, Goldsboro, NC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chia</LastName>
            <ForeName>Stephen K</ForeName>
            <Initials>SK</Initials>
            <AffiliationInfo>
              <Affiliation>NRG Oncology/NSABP, Pittsburgh, PA, USA; British Columbia Cancer Agency, Vancouver, BC, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brufsky</LastName>
            <ForeName>Adam M</ForeName>
            <Initials>AM</Initials>
            <AffiliationInfo>
              <Affiliation>NRG Oncology/NSABP, Pittsburgh, PA, USA; The University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Walshe</LastName>
            <ForeName>Janice M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>NRG Oncology/NSABP, Pittsburgh, PA, USA; Cancer Trials Ireland (formerly known as Irish Clinical Oncology Research Group-ICORG), Dublin, Ireland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Soori</LastName>
            <ForeName>Gamini S</ForeName>
            <Initials>GS</Initials>
            <AffiliationInfo>
              <Affiliation>NRG Oncology/NSABP, Pittsburgh, PA, USA; Cancer Alliance of Nebraska(Missouri Valley Cancer Consortium), Omaha, NE, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dakhil</LastName>
            <ForeName>Shaker R</ForeName>
            <Initials>SR</Initials>
            <AffiliationInfo>
              <Affiliation>NRG Oncology/NSABP, Pittsburgh, PA, USA; CCCOP, Wichita Cancer Center of Kansas, Wichita, KS, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Seay</LastName>
            <ForeName>Thomas E</ForeName>
            <Initials>TE</Initials>
            <AffiliationInfo>
              <Affiliation>NRG Oncology/NSABP, Pittsburgh, PA, USA; Georgia NCI Community Oncology Research Program, Atlanta, GA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wade</LastName>
            <ForeName>James L</ForeName>
            <Initials>JL</Initials>
            <Suffix>3rd</Suffix>
            <AffiliationInfo>
              <Affiliation>NRG Oncology/NSABP, Pittsburgh, PA, USA; CCOP, Central Illinois, Decatur, IL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McCarron</LastName>
            <ForeName>Edward C</ForeName>
            <Initials>EC</Initials>
            <AffiliationInfo>
              <Affiliation>NRG Oncology/NSABP, Pittsburgh, PA, USA; MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Paik</LastName>
            <ForeName>Soonmyung</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>NRG Oncology/NSABP, Pittsburgh, PA, USA; Yonsei University College of Medicine, Seoul, South Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Swain</LastName>
            <ForeName>Sandra M</ForeName>
            <Initials>SM</Initials>
            <AffiliationInfo>
              <Affiliation>NRG Oncology/NSABP, Pittsburgh, PA, USA; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wickerham</LastName>
            <ForeName>D Lawrence</ForeName>
            <Initials>DL</Initials>
            <AffiliationInfo>
              <Affiliation>NRG Oncology/NSABP, Pittsburgh, PA, USA; Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wolmark</LastName>
            <ForeName>Norman</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>NRG Oncology/NSABP, Pittsburgh, PA, USA; Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT00382070</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>U10 CA180822</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U10 CA180868</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U24 CA196067</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>UG1 CA189867</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Lancet Oncol</MedlineTA>
        <NlmUniqueID>100957246</NlmUniqueID>
        <ISSNLinking>1470-2045</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047072">Aromatase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011980">Receptors, Progesterone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>094ZI81Y45</RegistryNumber>
          <NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7LKK855W8I</RegistryNumber>
          <NameOfSubstance UI="D000077289">Letrozole</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Lancet Oncol. 2019 Jan;20(1):8-9</RefSource>
          <PMID Version="1">30509770</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="ErratumIn">
          <RefSource>Lancet Oncol. 2019 Jan;20(1):e10</RefSource>
          <PMID Version="1">30614468</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047072" MajorTopicYN="N">Aromatase Inhibitors</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057194" MajorTopicYN="N">Intention to Treat Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077289" MajorTopicYN="N">Letrozole</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017698" MajorTopicYN="N">Postmenopause</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011980" MajorTopicYN="N">Receptors, Progesterone</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013629" MajorTopicYN="N">Tamoxifen</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Potential conflict(s) of interest. The following authors declare the following potential conflict(s) of interest: EPM - - served as a consultant and speaker for Genomic Health, Inc, and consultant for Biotheranostics, outside the submitted work.. CEG, Jr. - - reports grants from National Cancer Institute, during the conduct of the study; personal fees from Celgene, personal fees from Myriad, other from AstraZeneca, outside the submitted work. JMW - - reports personal fees from Genomic Health Inc, Biotheranostics, Roche, and Pfizer, outside the submitted work, SMS - - reports grants, personal fees, and non-financial support from Genentech/Roche; personal fees from Novartis and AstraZeneca; personal fees and non-financial support from Eli Lilly &amp; Co., Pieris Pharmaceuticals, and Inivata Ltd.; grants from Puma Biotechnology, Pfizer, and Merrimack Pharmaceuticals; and non-financial support from Caris Life Sciences and AstraZeneca.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>8</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>8</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30509771</ArticleId>
        <ArticleId IdType="mid">NIHMS1516007</ArticleId>
        <ArticleId IdType="pmc">PMC6691732</ArticleId>
        <ArticleId IdType="doi">10.1016/S1470-2045(18)30621-1</ArticleId>
        <ArticleId IdType="pii">S1470-2045(18)30621-1</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Early Breast Cancer Trialists’ Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet
351:1451–67, 1998</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9605801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan H, Gray R, Braybrooke J, et al.: 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med
377:1836–1846, 2017</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5734609</ArticleId>
            <ArticleId IdType="pubmed">29117498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goss PE, Ingle JN, Martino S, et al.: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med
349:1793–802, 2003</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14551341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mamounas EP, Jeong JH, Wickerham DL, et al.: Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol
26:1965–71, 2008</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18332472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davies C, Pan H, Godwin J, et al.: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet
381:805–16, 2013</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3596060</ArticleId>
            <ArticleId IdType="pubmed">23219286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gray RG, Rea DW, Handley K, et al.: ATTom: randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer—preliminary results. J Clin Oncol
26 (Suppl 10):Abstract
513, 2008</Citation>
        </Reference>
        <Reference>
          <Citation>Goss PE, Ingle JN, Pritchard Kl, et al.: Extending Aromatase-lnhibitor Adjuvant Therapy to 10 Years. N Engl J Med
375:209–19, 2016</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5024713</ArticleId>
            <ArticleId IdType="pubmed">27264120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, et al.: Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). J Natl Cancer Inst
110, 2018.  doi: 10.1093/jnci/djx134</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djx134</ArticleId>
            <ArticleId IdType="pubmed">28922787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM, et al.: Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. Lancet Oncol
18:1502–11, 2017</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29031778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colleoni M, Luo W, Karlsson P, et al.: Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol
19:127–138, 2018</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29158011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gnant M, Steger G, Greil R, et al.: A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy – results from 3,484 postmenopausal women in the ABCSG-16 trial. San Antonio Brest Cancer Symposium, Abstract GS3-01:Abstract GS3-01, 2017</Citation>
        </Reference>
        <Reference>
          <Citation>White SJ, Freedman LS: Allocation of patients to treatment groups in a controlled clinical study. BrJ Cancer
37:849–57, 1978</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2009630</ArticleId>
            <ArticleId IdType="pubmed">350254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics
35:549–56, 1979</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">497341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson JR, High R: Alternatives to the standard Fleming, Harrington, and O’Brien futility boundary. Clinical trials
8:270–6, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21441286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klein JP, Moeschberger ML: Survival Analysis: Techniques for Censored and Truncated Data. . Statistics for Biology and Health Eds: Dietz K, Gail M, Krickeberg K, Samet J, Tsiatis A
Springer; 
New York:  , 2003</Citation>
        </Reference>
        <Reference>
          <Citation>Cox DR: Regression models and life-tables (with discussion) . J Royal Stat Society B
34:187–202, 1972</Citation>
        </Reference>
        <Reference>
          <Citation>Lin DY, Wei LJ, Ying Z: Checking the Cox Model with Cumulative Sums of Martingale-Based Residuals. Biometrika
80:557–572, 1993</Citation>
        </Reference>
        <Reference>
          <Citation>Kaplan EL, Meier P: Nonparametric-Estimation from Incomplete Observations. J am Stat Asscoc
53:457–481, 1958</Citation>
        </Reference>
        <Reference>
          <Citation>Kalbfleisch JD, Prentice RL: The statistical analysis of failure time data. Hoboken, N.J.: J. Wiley, , 2002</Citation>
        </Reference>
        <Reference>
          <Citation>Hudis CA, Barlow WE, Costantino JP, et al.: Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol
25:2127–32, 2007</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17513820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amir E, Seruga B, Niraula S, et al.: Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst
103:1299–309, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21743022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dowsett M, Sestak I, Regan MM, et al.: Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. J Clin Oncol
36: 1941–48, 2018</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6049399</ArticleId>
            <ArticleId IdType="pubmed">29676944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sparano JA, O’Neill A, Alpaugh K, et al.: Circulating tumor cells (CTCs) five years after diagnosis are prognostic for late recurrence in operable stage M-IM breast cancer. San Antonio Brest Cancer Symposium, Abstract GS6-03, 2017</Citation>
        </Reference>
        <Reference>
          <Citation>Dubsky P, Brase JC, Jakesz R, et al.: The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br J Cancer
109:2959–64, 2013</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3859949</ArticleId>
            <ArticleId IdType="pubmed">24157828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolmark N, Mamounas EP, Baehner FL, et al.: Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14. J Clin Oncol
34:2350–8, 2016</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4981975</ArticleId>
            <ArticleId IdType="pubmed">27217450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sgroi DC, Sestak I, Cuzick J, et al.: Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. The Lancet. Oncology
14:1067–76, 2013</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3918681</ArticleId>
            <ArticleId IdType="pubmed">24035531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filipits M, Nielsen TO, Rudas M, et al.: The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clinical Cancer Res 20:1298–305, 2014</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24520097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blok EJ, Bastiaannet E, van den Hout WB, et al.: Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe. Cancer Treat Rev
62:74–90, 2018</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29175678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sgroi DC, Carney E, Zarrella E, et al.: Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst
105:1036–42, 2013</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3888138</ArticleId>
            <ArticleId IdType="pubmed">23812955</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
